Grace & White Inc. NY Sells 1,880 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Grace & White Inc. NY trimmed its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 4.4% during the third quarter, HoldingsChannel.com reports. The fund owned 41,330 shares of the medical instruments supplier’s stock after selling 1,880 shares during the quarter. West Pharmaceutical Services accounts for about 2.2% of Grace & White Inc. NY’s holdings, making the stock its 13th largest position. Grace & White Inc. NY’s holdings in West Pharmaceutical Services were worth $12,406,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the stock. Whittier Trust Co. of Nevada Inc. grew its position in West Pharmaceutical Services by 3.7% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 21,331 shares of the medical instruments supplier’s stock valued at $6,402,000 after acquiring an additional 761 shares during the period. Whittier Trust Co. boosted its stake in West Pharmaceutical Services by 4.4% in the third quarter. Whittier Trust Co. now owns 41,804 shares of the medical instruments supplier’s stock worth $12,547,000 after purchasing an additional 1,779 shares in the last quarter. Northwest Investment Counselors LLC acquired a new position in West Pharmaceutical Services in the third quarter worth $30,000. Vest Financial LLC boosted its stake in West Pharmaceutical Services by 31.0% in the third quarter. Vest Financial LLC now owns 151,217 shares of the medical instruments supplier’s stock worth $45,389,000 after purchasing an additional 35,771 shares in the last quarter. Finally, Harfst & Associates Inc. boosted its stake in West Pharmaceutical Services by 7.9% in the third quarter. Harfst & Associates Inc. now owns 7,484 shares of the medical instruments supplier’s stock worth $2,246,000 after purchasing an additional 551 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors.

West Pharmaceutical Services Price Performance

West Pharmaceutical Services stock opened at $287.25 on Tuesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34. The firm has a market cap of $20.84 billion, a P/E ratio of 40.86, a P/E/G ratio of 10.46 and a beta of 1.01. The business’s fifty day moving average is $299.96 and its two-hundred day moving average is $324.52. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $413.70.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The business had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. West Pharmaceutical Services’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.11 EPS. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Charles Witherspoon sold 1,029 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the transaction, the vice president now owns 1,478 shares of the company’s stock, valued at $443,400. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.